Molecular Functionality of Cytochrome P450 4 (CYP4) Genetic Polymorphisms and Their Clinical Implications

被引:54
作者
Jarrar, Yazun Bashir [1 ]
Lee, Su-Jun [2 ,3 ]
机构
[1] Alzaytoonah Univ Jordan, Dept Pharm, Coll Pharm, Amman 11734, Jordan
[2] Inje Univ, Dept Pharmacol, Coll Med, Busan 47392, South Korea
[3] Inje Univ, Pharmacogen Res Ctr, Coll Med, Busan 47392, South Korea
基金
新加坡国家研究基金会;
关键词
CYP4; genes; genetic polymorphisms; 20-HETE; fatty acid; arachidonic acid; SNPs; molecular functionality; metabolism; lamellar ichthyosis; Bietti's crystalline dystrophy; CORNEO-RETINAL DYSTROPHY; BIETTIS CRYSTALLINE DYSTROPHY; PROLIFERATOR-ACTIVATED RECEPTORS; ACID OMEGA-HYDROXYLASE; 20-HYDROXYEICOSATETRAENOIC ACID; HUMAN LIVER; ARACHIDONIC-ACID; CDNA CLONING; T8590C POLYMORPHISM; JAPANESE PATIENTS;
D O I
10.3390/ijms20174274
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Enzymes in the cytochrome P450 4 (CYP4) family are involved in the metabolism of fatty acids, xenobiotics, therapeutic drugs, and signaling molecules, including eicosanoids, leukotrienes, and prostanoids. As CYP4 enzymes play a role in the maintenance of fatty acids and fatty-acid-derived bioactive molecules within a normal range, they have been implicated in various biological functions, including inflammation, skin barrier, eye function, cardiovascular health, and cancer. Numerous studies have indicated that genetic variants of CYP4 genes cause inter-individual variations in metabolism and disease susceptibility. Genetic variants of CYP4A11, 4F2 genes are associated with cardiovascular diseases. Mutations of CYP4B1, CYP4Z1, and other CYP4 genes that generate 20-HETE are a potential risk for cancer. CYP4V2 gene variants are associated with ocular disease, while those of CYP4F22 are linked to skin disease and CYP4F3B is associated with the inflammatory response. The present study comprehensively collected research to provide an updated view of the molecular functionality of CYP4 genes and their associations with human diseases. Functional analysis of CYP4 genes with clinical implications is necessary to understand inter-individual variations in disease susceptibility and for the development of alternative treatment strategies.
引用
收藏
页数:21
相关论文
共 166 条
  • [51] Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal Microsomes
    Hashizume, T
    Imaoka, S
    Mise, M
    Terauchi, Y
    Fujii, T
    Miyazaki, H
    Kamataki, T
    Funae, Y
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 300 (01) : 298 - 304
  • [52] cDNA cloning and expression of a novel cytochrome P450 (CYP4F12) from human small intestine
    Hashizume, T
    Imaoka, S
    Hiroi, T
    Terauchi, Y
    Fujii, T
    Miyazaki, H
    Kamataki, T
    Funae, Y
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 280 (04) : 1135 - 1141
  • [53] HUMAN LIVER MICROSOMAL METABOLISM OF THE ENANTIOMERS OF WARFARIN AND ACENOCOUMAROL - P450 ISOZYME DIVERSITY DETERMINES THE DIFFERENCES IN THEIR PHARMACOKINETICS
    HERMANS, JJR
    THIJSSEN, HHW
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1993, 110 (01) : 482 - 490
  • [54] Hiratsuka Masahiro, 2004, Drug Metab Pharmacokinet, V19, P114, DOI 10.2133/dmpk.19.114
  • [55] Genetic polymorphisms and haplotype structures of the CYP4A22 gene in a Japanese population
    Hiratsuka, Masahiro
    Nozawa, Hisayoshi
    Katsumoto, Yuya
    Moteki, Toshiko
    Sasaki, Takarnitsu
    Konno, Yumiko
    Mizugaki, Michinao
    [J]. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2006, 599 (1-2) : 98 - 104
  • [56] The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development
    Hong, Fan
    Xu, Pengfei
    Zhai, Yonggong
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (08)
  • [57] Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy
    Horne, Benjamin D.
    Lenzini, Petra A.
    Wadelius, Mia
    Jorgensen, Andrea L.
    Kimmel, Stephen E.
    Ridker, Paul M.
    Eriksson, Niclas
    Anderson, Jeffrey L.
    Pirmohamed, Munir
    Limdi, Nita A.
    Pendleton, Robert C.
    McMillin, Gwendolyn A.
    Burmester, James K.
    Kurnik, Daniel
    Stein, C. Michael
    Caldwell, Michael D.
    Eby, Charles S.
    Rane, Anders
    Lindh, Jonatan D.
    Shin, Jae-Gook
    Kim, Ho-Sook
    Angchaisuksiri, Pantep
    Glynn, Robert J.
    Kronquist, Kathryn E.
    Carlquist, John F.
    Grice, Gloria R.
    Barrack, Robert L.
    Li, Juan
    Gage, Brian F.
    [J]. THROMBOSIS AND HAEMOSTASIS, 2012, 107 (02) : 232 - 240
  • [58] Hsu H, 2003, ANTICANCER RES, V23, P2723
  • [59] Human cytochrome P450 family 4 enzymes:: Function, genetic variation and regulation
    Hsu, Mei-Hui
    Savas, Uezen
    Griffin, Keith J.
    Johnson, Eric F.
    [J]. DRUG METABOLISM REVIEWS, 2007, 39 (2-3) : 515 - 538
  • [60] Regulation of human cytochrome P4504F2 expression by sterol regulatory element-binding protein and lovastatin
    Hsu, Mei-Hui
    Savas, Uzen
    Griffin, Keith J.
    Johnson, Eric F.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (08) : 5225 - 5236